Axitinib–ICIs boost the RCC armamentarium
Axitinib–ICIs boost the RCC armamentarium, Published online: 04 March 2019; doi:10.1038/s41571-019-0193-5Axitinib–ICIs boost the RCC armamentarium (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - March 3, 2019 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
The NKG2A immune checkpoint — a new direction in cancer immunotherapy
The NKG2A immune checkpoint — a new direction in cancer immunotherapy, Published online: 01 March 2019; doi:10.1038/s41571-019-0182-8Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer. However, established biomarkers of response are lacking, and larger trials are needed to enable firm conclusions to be drawn about whether NKG2A inhibition complements existing im...
Source: Nature Clinical Practice Oncology - February 28, 2019 Category: Cancer & Oncology Authors: Benjamin C. Creelan Scott J. Antonia Source Type: research
Vessel co-option in cancer
Vessel co-option in cancer, Published online: 28 February 2019; doi:10.1038/s41571-019-0181-9Despite much hope, anti-angiogenic agents have largely failed to achieve the promise demonstrated in preclinical models. In this Review, the authors discuss an alternative hypothesis — vessel co-option — that might explain many of these failures and describe the evidence for a role of this largely overlooked aspect of tumour biology. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 28, 2019 Category: Cancer & Oncology Authors: Elizabeth A. Kuczynski Peter B. Vermeulen Francesco Pezzella Robert S. Kerbel Andrew R. Reynolds Source Type: research
Anti-CD19 CAR T cell therapy for lymphoma — off to the races!
Anti-CD19 CAR T cell therapy for lymphoma — off to the races!, Published online: 27 February 2019; doi:10.1038/s41571-019-0183-7Recently published data from the ZUMA-1 and JULIET trials suggest that CD19-directed chimeric antigen receptor (CAR) T cell therapy can provide durable remissions, with a low risk of relapse or progression, in 30–40% of patients with relapsed and/or refractory aggressive large B cell lymphoma. Two-year follow-up of the ZUMA-1 clinical trial has not revealed any unexpected toxicities, but further safety monitoring will be needed. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 27, 2019 Category: Cancer & Oncology Authors: David G. Maloney Source Type: research
Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’
Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’, Published online: 26 February 2019; doi:10.1038/s41571-019-0186-4Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’ (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 26, 2019 Category: Cancer & Oncology Authors: Guido Rindi Bertram Wiedenmann Source Type: research
Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma
Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma, Published online: 26 February 2019; doi:10.1038/s41571-019-0192-6Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 26, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
Time for a change and to adopt a novel molecular genomic approach in NETs
Time for a change and to adopt a novel molecular genomic approach in NETs, Published online: 26 February 2019; doi:10.1038/s41571-019-0185-5Time for a change and to adopt a novel molecular genomic approach in NETs (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 26, 2019 Category: Cancer & Oncology Authors: Lisa Bodei Eric Liu Scott Paulson Anthony Gulati Jon Freudman William Grosh Sheldon Kafer Prasanna C. Wickremesinghe Ronald R. Salem Source Type: research
ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?
ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?, Published online: 26 February 2019; doi:10.1038/s41571-019-0191-7ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 26, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
Liquid biopsy and minimal residual disease — latest advances and implications for cure
Liquid biopsy and minimal residual disease — latest advances and implications for cure, Published online: 22 February 2019; doi:10.1038/s41571-019-0187-3In this Review, Pantel and Alix-Panabières provide an overview of approaches for the detection and characterization of minimal residual disease (MRD) using circulating tumour cells and circulating tumour DNA. They also discuss the clinical implications of such liquid biopsy approaches to MRD monitoring for the management of patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 22, 2019 Category: Cancer & Oncology Authors: Klaus Pantel Catherine Alix-Panabi ères Source Type: research
Early PET response predicts complete response
Early PET response predicts complete response, Published online: 22 February 2019; doi:10.1038/s41571-019-0189-1Early PET response predicts complete response (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 22, 2019 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
CTCs ‘piggyback’ off neutrophils
CTCs ‘piggyback’ off neutrophils, Published online: 20 February 2019; doi:10.1038/s41571-019-0188-2CTCs ‘piggyback’ off neutrophils (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 20, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
Therapeutic implications of germline genetic findings in cancer
Therapeutic implications of germline genetic findings in cancer, Published online: 19 February 2019; doi:10.1038/s41571-019-0179-3The majority of genetically targeted approaches to cancer therapy focus on somatic mutations. However, evidence is accumulating in support of a role for germline genetic alterations in determining responsiveness to treatment. In this Review, the authors summarize the therapeutic potential of knowledge of the germline genome in patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 19, 2019 Category: Cancer & Oncology Authors: Subotheni Thavaneswaran Emma Rath Kathy Tucker Anthony M. Joshua Dominique Hess Mark Pinese Mandy L. Ballinger David M. Thomas Source Type: research
Registration studies — when should patients be deemed ineligible for aggressive therapy?
Registration studies — when should patients be deemed ineligible for aggressive therapy?, Published online: 18 February 2019; doi:10.1038/s41571-019-0180-xThe approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 18, 2019 Category: Cancer & Oncology Authors: Rachel J. Cook Jennifer Gill Vinay Prasad Source Type: research
Challenges to curing primary brain tumours
Challenges to curing primary brain tumours, Published online: 07 February 2019; doi:10.1038/s41571-019-0177-5Brain cancer encompasses a diverse range of complex malignancies, many of which are associated with a poor prognosis and require more effective treatments. In this Position Paper, an international panel of clinicians and laboratory-based scientists convened by Cancer Research UK identify and discuss seven challenges that must be overcome if we are to cure all patients with a brain tumour. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 7, 2019 Category: Cancer & Oncology Authors: Kenneth Aldape Kevin M. Brindle Louis Chesler Rajesh Chopra Amar Gajjar Mark R. Gilbert Nicholas Gottardo David H. Gutmann Darren Hargrave Eric C. Holland David T. W. Jones Johanna A. Joyce Pamela Kearns Mark W. Kieran Ingo K. Mellinghoff Melinda Merchant Source Type: research
CSF DNA provides a snapshot of the glioma genome
CSF DNA provides a snapshot of the glioma genome, Published online: 05 February 2019; doi:10.1038/s41571-019-0178-4CSF DNA provides a snapshot of the glioma genome (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 5, 2019 Category: Cancer & Oncology Authors: David Killock Source Type: research
